View Older Stories View More Recent Stories

Sep 13, 2021 06:45AM Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
Sep 10, 2021 05:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2021 05:30PM Mirum Pharmaceuticals to Participate in September Investor Conferences
Aug 19, 2021 05:32PM Mirum Pharmaceuticals (MIRM) Appoints Biotechnology Executive William C. Fairey to its Board of Directors
Aug 19, 2021 05:30PM Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors
Aug 10, 2021 07:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 5, 2021 04:02PM Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
Jul 29, 2021 04:00PM Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
Jul 26, 2021 08:00PM Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea
Jul 12, 2021 06:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 24, 2021 04:05PM Mirum Pharmaceuticals to Present at Piper Sandler’s Virtual EASL Takeaway Day
Jun 23, 2021 09:07AM Mirum Pharmaceuticals, Inc. (MIRM) Presents Analyses From Its Rare Liver Disease Programs at the EASL
Jun 23, 2021 09:00AM Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021
Jun 16, 2021 09:00AM Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021
Jun 10, 2021 05:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 7, 2021 09:02AM Mirum Pharmaceuticals (MIRM) Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors
Jun 7, 2021 09:00AM Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors
Jun 3, 2021 10:10AM Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Me
May 26, 2021 09:00AM Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) Annual Meeting 2021
May 10, 2021 09:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2021 04:05PM Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
Apr 29, 2021 04:05PM Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
Apr 29, 2021 08:17AM Mirum Pharmaceuticals (MIRM) and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
Apr 29, 2021 08:00AM Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
Apr 29, 2021 08:00AM Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
Apr 26, 2021 09:03AM Mirum Pharmaceuticals (MIRM) Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome
Apr 26, 2021 09:00AM Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome
Apr 12, 2021 05:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 12, 2021 08:01AM Mirum Pharma (MIRM), Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
Apr 12, 2021 08:00AM Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
Mar 29, 2021 09:01AM Mirum Pharmaceuticals, Inc. (MIRM) Announces FDA Acceptance of NDA and Priority Review for Maralixibat in Alagille Syndrome
Mar 29, 2021 09:00AM Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome
Mar 10, 2021 06:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 9, 2021 04:02PM Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates
Feb 22, 2021 09:00AM Mirum Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 10, 2021 05:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 1, 2021 09:02AM Mirum Pharmaceuticals, Inc. (MIRM) Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome
Feb 1, 2021 09:00AM Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome
Jan 24, 2021 09:00AM Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign
Jan 14, 2021 09:06AM Mirum Pharmaceuticals, Inc. (MIRM) Reports First Patient Enrolled in Phase 2B VISTAS Clinical Study Evaluating Volixibat
Jan 14, 2021 09:00AM Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis
Jan 12, 2021 09:00AM Mirum Pharmaceuticals Provides Corporate Update
Jan 8, 2021 06:17PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 4, 2021 08:30AM Mirum Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021
Dec 10, 2020 07:41PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 9, 2020 09:00AM Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding Arrangement
Dec 7, 2020 09:00AM Mirum Pharmaceuticals Announces Virtual Investor Day 2020
Nov 30, 2020 08:34AM Mirum Pharmaceuticals, Inc. (MIRM) Announces EMA Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2
Nov 30, 2020 08:30AM Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2
Nov 23, 2020 09:30AM Mirum Pharmaceuticals to Present at Upcoming Investor Conferences
View More Recent Stories View Older Stories